OXIGENE, INC.

Company

Oncotelic Therapeutics, Inc.

Filed

April 7, 2009

Period of Report

May 28, 2009

Accession Number

0000950135-09-002640

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →